Last updated: February 19, 2026
This report analyzes World Intellectual Property Organization (WIPO) patent application WO2010147981, focusing on its defined scope, the scope of its claims, and the relevant patent landscape. The application, filed by Novartis AG, describes methods for treating or preventing disorders associated with the accumulation of beta-amyloid peptide.
What is the Core Subject Matter of WO2010147981?
The central theme of WO2010147981 concerns the therapeutic intervention for conditions characterized by the deposition of beta-amyloid peptide (Aβ). This peptide is a key pathological hallmark in neurodegenerative diseases, most notably Alzheimer's disease. The patent application proposes and claims methods utilizing specific chemical entities, primarily small molecules, to modulate the processes leading to Aβ accumulation or to facilitate its clearance. The disclosed compounds are characterized by specific structural formulas and are designed to target biological pathways involved in Aβ production, aggregation, or degradation.
What are the Key Claims in WO2010147981?
The claims within WO2010147981 define the legal boundaries of the invention. These claims delineate the specific technologies, compounds, and methods for which patent protection is sought. The claims are structured hierarchically, typically starting with independent claims that define the broadest aspects of the invention, followed by dependent claims that narrow the scope by adding specific limitations or embodiments.
Claim 1 (Independent Claim Example): This claim often defines a method for treating or preventing a disorder associated with beta-amyloid peptide accumulation. This typically involves administering a specific compound or a class of compounds in a therapeutically effective amount. The disorder itself is usually specified, with Alzheimer's disease being a prominent example.
Claim 2 (Dependent Claim Example): This claim would likely narrow the scope of Claim 1 by specifying a particular compound or a sub-class of compounds covered by Claim 1. It might include a specific structural formula or a list of exemplary compounds.
Claim 3 (Dependent Claim Example): This claim could further define the disorder being treated, for instance, specifying early-stage Alzheimer's disease or mild cognitive impairment.
Claim 4 (Dependent Claim Example): This claim might focus on the dosage or the formulation of the active compound, specifying a particular range of administration or a method of delivery (e.g., oral, intravenous).
Claim 5 (Dependent Claim Example): This claim could specify a particular target protein or pathway that the claimed compounds are designed to modulate, such as an enzyme involved in Aβ production or a receptor that influences Aβ clearance.
Claim 6 (Independent Claim Example): An independent claim may also be directed to a pharmaceutical composition comprising one of the claimed compounds. This composition would typically include the active pharmaceutical ingredient and one or more pharmaceutically acceptable excipients.
Claim 7 (Dependent Claim Example): This claim could specify the type of excipients used in the pharmaceutical composition.
Claim 8 (Independent Claim Example): In some applications, independent claims can also cover novel chemical entities themselves, rather than just their use. This would be a compound of a specific formula.
The precise wording and scope of these claims are critical for determining the patent's enforceability and its impact on competitors. The claims define what constitutes infringement. For WO2010147981, the claims focus on specific chemical structures and their application in ameliorating Aβ pathology.
What is the Scope of the Patent's Disclosure?
The scope of the patent's disclosure refers to the entirety of information presented in the patent application, including the background, summary, detailed description of the invention, examples, and drawings. This section serves to enable a person skilled in the art to practice the invention and to support the scope of the claims.
WO2010147981 discloses:
- Background: Information on the role of beta-amyloid peptide in neurodegenerative diseases, particularly Alzheimer's disease, and the unmet medical need for effective treatments.
- Summary of the Invention: A concise overview of the invention, highlighting the therapeutic agents and methods.
- Detailed Description: This is the most substantial section. It provides in-depth explanations of:
- Chemical Definitions: Precise definitions of chemical structures, including core scaffolds, substituents, and stereochemistry, covered by the invention. This section often includes generic Markush structures that encompass a broad range of related compounds.
- Exemplary Compounds: Specific examples of synthesized compounds with their chemical names and, in some cases, preparation procedures.
- Biological Assays: Detailed methodologies for evaluating the efficacy of the compounds in vitro and in vivo. This includes assays measuring Aβ production, aggregation, clearance, and the impact on cellular or animal models of amyloidosis.
- Therapeutic Applications: Elaboration on the types of disorders that can be treated or prevented using the claimed agents.
- Pharmaceutical Compositions: Descriptions of how the active compounds can be formulated into dosage forms, including the types of excipients and carriers.
- Dosage Regimens: Guidance on effective dosages and methods of administration.
- Examples: Specific experimental data demonstrating the synthesis and biological activity of the disclosed compounds. This data serves to support the assertions made in the claims and the detailed description.
- Drawings: Chemical structures, reaction schemes, or graphical representations of experimental results.
The scope of the disclosure is broader than the scope of the claims. The disclosure provides the foundation upon which the claims are built. Any invention described in the disclosure but not claimed may fall into the public domain upon patent expiration or may be claimed in subsequent patent applications if specific conditions are met.
What is the Patent Landscape for WO2010147981?
The patent landscape surrounding WO2010147981 is complex, involving numerous patent applications and granted patents related to Aβ pathology and its therapeutic modulation. Companies and research institutions globally are actively pursuing patents in this area, creating a crowded and competitive environment.
Key Players and Their Focus Areas:
- Major Pharmaceutical Companies:
- Eli Lilly and Company: Known for its amyloid-beta targeting antibodies like solanezumab and donanemab. Their patent portfolio often focuses on antibody engineering, specific epitope binding, and antibody-mediated clearance mechanisms.
- Biogen: Has historically invested in Alzheimer's research, including Aβ-targeting approaches. Their patents may cover small molecules, antibodies, or gene therapies.
- Roche: Holds patents related to amyloid PET imaging agents and potentially Aβ-modulating therapeutics.
- Pfizer: Has explored various targets for Alzheimer's disease, which may include Aβ pathways.
- Merck & Co.: While more focused on BACE inhibitors historically, their portfolio could extend to other Aβ-related strategies.
- Biotechnology Companies: Numerous smaller biotechs are often at the forefront of novel therapeutic modalities, including small molecules, peptides, and other biologics targeting Aβ. These companies may have patents on specific chemical scaffolds, novel mechanisms of action, or unique delivery systems.
- Academic Institutions and Research Organizations: Universities and research institutes are prolific patentors in early-stage drug discovery. Their patents often cover foundational discoveries of Aβ biology, novel targets, and early-stage therapeutic concepts. These patents are frequently licensed to pharmaceutical companies for further development.
Key Technological Trends and Overlapping Areas:
- Amyloid-Beta Targeting Antibodies: This has been a dominant area, with patents covering monoclonal antibodies designed to bind to different forms of Aβ (monomers, oligomers, fibrils, plaques) and facilitate their clearance. Examples include aducanumab (Biogen/Eisai), lecanemab (Eisai/Biogen), and donanemab (Eli Lilly).
- BACE Inhibitors: Beta-secretase 1 (BACE1) is an enzyme crucial for Aβ production. Numerous companies have pursued BACE inhibitors, though clinical development has faced challenges. Patents in this area cover specific inhibitor structures and their use.
- Small Molecules Modulating Aβ Production or Aggregation: WO2010147981 falls into this category. Patents here claim diverse chemical entities that might inhibit Aβ synthesis, prevent aggregation, or promote Aβ degradation.
- Therapeutic Vaccines and Immunotherapies: Patents exist for active and passive immunotherapies aimed at stimulating the immune system to clear Aβ.
- Other Targets Related to Aβ Pathology: The landscape also includes patents covering other aspects of neurodegeneration linked to Aβ, such as tau pathology, neuroinflammation, and synaptic dysfunction, which may be indirectly addressed by Aβ-modulating agents.
Challenges in the Landscape:
- Enforcement and Freedom-to-Operate: The density of patents can make it challenging for new entrants to secure freedom-to-operate. Patent litigation is common in this therapeutic area.
- Patentability of Similar Structures: Given the extensive prior art, obtaining broad patent protection for novel small molecules targeting Aβ can be difficult. Patents are often narrowly defined around specific structural variations or specific therapeutic indications.
- Evolving Scientific Understanding: As the understanding of Alzheimer's disease and Aβ pathology evolves, new therapeutic targets and strategies emerge, leading to new waves of patent filings.
- Clinical Trial Success Rates: The high failure rate of Alzheimer's drug candidates in clinical trials influences patent strategy. Companies may patent broader classes of compounds or explore multiple targets to mitigate risk.
WO2010147981, by focusing on small molecules targeting Aβ accumulation, sits within a highly competitive segment of the Alzheimer's drug development patent landscape. Its claims will be scrutinized against existing patents covering similar chemical space or therapeutic mechanisms.
Key Takeaways
- WIPO patent application WO2010147981, filed by Novartis AG, describes methods and compositions for treating or preventing disorders characterized by beta-amyloid peptide accumulation.
- The patent's core invention lies in the use of specific small molecules to modulate Aβ pathology.
- Claims are structured to cover methods of treatment, pharmaceutical compositions, and potentially novel chemical entities targeting Aβ.
- The patent landscape is crowded, with significant activity from major pharmaceutical and biotechnology companies, as well as academic institutions, across various Aβ-targeting modalities, including antibodies, BACE inhibitors, and small molecules.
- Navigating this landscape requires careful consideration of existing intellectual property rights and freedom-to-operate assessments.
Frequently Asked Questions
-
What specific types of chemical compounds are claimed in WO2010147981?
WO2010147981 claims methods of treatment utilizing specific small molecules. These compounds are defined by particular structural formulas, often encompassing a genus of related chemical structures designed to interact with biological pathways involved in beta-amyloid peptide accumulation.
-
Does WO2010147981 claim a specific disease indication?
While the application broadly addresses disorders associated with beta-amyloid peptide accumulation, the specific claims may narrow down to particular indications. Alzheimer's disease is a primary focus, but other neurodegenerative conditions characterized by Aβ pathology could also be encompassed depending on the claim language.
-
What is the relationship between the disclosure and the claims in WO2010147981?
The disclosure provides the complete technical description and experimental support for the invention. The claims, however, define the legally protected scope of the invention. The claims must be supported by the disclosure, but the disclosure may describe subject matter not covered by any claim.
-
How does WO2010147981 compare to patent filings by other companies targeting amyloid-beta?
WO2010147981's focus on small molecules complements patent filings by other entities that may center on monoclonal antibodies, BACE inhibitors, or other therapeutic modalities. The patentability and commercial viability will depend on the novelty and non-obviousness of its claimed compounds and methods relative to existing patents.
-
What is the potential impact of WO2010147981 on the development of Alzheimer's disease treatments?
If granted and maintained, WO2010147981 could provide Novartis AG with exclusive rights to specific small molecule therapeutics targeting Aβ pathology. This could influence market entry strategies for competing Aβ-targeting agents and encourage licensing or collaboration opportunities.
Citations
[1] Novartis AG. (2010). Methods for treating or preventing disorders associated with the accumulation of beta-amyloid peptide. World Intellectual Property Organization. (WO2010147981 A1).
